Valiant Organics FY26 PAT Turns Positive at ₹332 Cr, Revenue Rises 3% to ₹7,388 Cr
Valiant Organics reported a turnaround in FY26 with PAT turning positive at ₹332 million, compared to a loss of ₹34 million in FY25. Revenue grew 3% to ₹7,388 million. EBITDA margins expanded to 11.94% from 7.47%. Q4 FY26 PAT was ₹157 million.
The shift from a loss-making position to profitability, coupled with revenue growth and margin expansion, is a material positive development for the company and its stakeholders.
The company has shown a significant turnaround, moving from a loss to a profit, with improved revenue and expanded margins, indicating a positive financial performance.
Valiant Organics Limited has reported a significant turnaround for the financial year 2025-26, marked by a substantial increase in profitability and a moderate rise in revenue. The company's operational revenue for FY26 grew by 3% year-on-year to ₹7,388 million (₹738.8 crore), driven by stable demand and improved realizations across its product categories.
The key highlight for FY26 is the company's return to profitability, with a reported Profit After Tax (PAT) of ₹332 million (₹33.2 crore), a significant improvement from a loss of ₹34 million (₹3.4 crore) in the previous financial year. This turnaround is attributed to focused operational execution and structural cost optimization initiatives.
EBITDA margins expanded sharply by 447 basis points to 11.94% in FY2025-26, compared to 7.47% in FY2024-25. This expansion was supported by lower raw material intensity and strong performance in the fourth quarter. Improved operating leverage, disciplined cost management, and better working capital efficiencies contributed to the recovery in overall earnings performance.
For the fourth quarter ended March 31, 2026 (Q4 FY26), operational revenue stood at ₹2,178 million (₹217.8 crore), a 6.9% increase year-on-year. The company reported a PAT of ₹157 million (₹15.7 crore) for Q4 FY26, compared to ₹42 million (₹4.2 crore) in the corresponding quarter of the previous year.
The investor presentation also provides a detailed breakdown of the company's business, including its manufacturing footprint across six units, a diversified product portfolio focusing on chlorophenol derivatives and PNA, and key chemistries like Chlorination, Hydrogenation, and Ammonolysis. The company serves various industries such as Pharmaceuticals, Dyes & Pigments, Agrochemicals, and specialty chemicals.
What to do with a filing like this
Valiant Organics Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Valiant Organics Limited. Read the original for the full detail.